Table 1. Summary of the five included studies.
| c-Met results | ||||||||
|---|---|---|---|---|---|---|---|---|
| Author (year) Country | Methods | Antibody, Dilution | No. of patients | Criteria for c-Methigh | c-Met low | c-Met high | HR for RFS (95% CI) | HR for OS (95% CI) |
| Ueki et al., (1997) Japan |
Western blot | Not applicable | 62 | ≥ Cutoff point of median value (36.4%), compared with the Hep3B band | 32 (51.6%) | 30 (48.4%) | NA | 2.26 (1.00–5.11) P = 0.051 |
| Ke et al., (2008) China |
IHC | Anti-human c-Met, EPI1454Y, 1:100 | 520 | > 20% of tumor section | 238 (45.85%) | 282 (54.2%) | 1.18 (0.95–1.46) P = 0.111 |
1.23 (0.97–1.53) P = 0.118 |
| Lee et al., (2013) Korea |
IHC | Rabbit monoclonal anti-c-Met, 1:100 | 287 | Proportion of stained tumor cells: 0 = < 20%; 1 = 20–60%; 2 = 61–80%; 3 = ≥ 81% (c-Methigh: 2 or 3) |
207 (72.1%) | 80 (27.9%) | 1.099 (0.86–1.41) P = 0.461 |
1.095 (0.92–1.30) P = 0.299 |
| Kondo et al., (2013) Japan |
IHC | Rabbit polyclonal anti-c-Met, 1:500 | 59 | Membrane staining: 0 = no; 1 = weak and incomplete or weak but complete < 10% of tumor cells; 2 = weak but complete in ≥ 10% or intense and complete circumferential staining in < 30%; 3 = intense and complete in ≥ 30% (c-Methigh: 2 or 3) |
44 (74.6%) | 15 (25.4%) | 3.10 (1.49–6.46) P = 0.002 |
0.96 (0.44–2.07) P = 0.91 |
| Koh et al., (2015) Korea |
IHC | Rabbit polyclonal anti-c-Met, 1:50 | 490 | Reactivity/membrane or cytoplasmic staining; 0 = no reactivity; 1= weak/faint or light; 2 = moderate/ intermediate in at least 30% or tumor cells; 3 = strong/intense complete in ≥ 30% (c-Methigh: 2 or 3) |
190 (38.8%) | 300 (61.2%) | 1.25 (1.01–1.55) P = 0.046 |
1.21 (0.91–1.60) P = 0.199 |
IHC, immunohistochemistry; RFS, relapse-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; NA, not available.